Afrotropics on the wing: phylogenomics and historical biogeography of awl and policeman skippers

The Old‐World Tropics encompass many unique biomes and associated biotas shaped by drastic climate and geological changes throughout the Cenozoic. Disjunct distributions of clades between the Afrotropics and the Oriental regions are testament to these changes. Awl and policeman skippers (Hesperiidae: Coeliadinae) are disjunctly distributed with some genera endemic to the Afrotropics and others restricted to the Oriental and Australian regions. We reconstruct the phylogeny of these butterflies using target exon capture phylogenomics. We also generate a dated framework for this clade that uses the putatively oldest known butterfly fossil to estimate the historical biogeography of Coeliadinae using a model‐based approach. We infer a stable and robust phylogeny for the subfamily, with all but one Afrotropical lineage forming a derived clade. The African genus Pyrrhiades syn. nov. is placed in synonymy with Coeliades to accommodate the new phylogeny. Our comparative dating exercise casts doubt on the assignment of the fossil Protocoeliades kristenseni as a derived Coeliadinae and suggests, along with our biogeographic estimation, a split of Coeliadinae from the rest of skippers in the Palaeocene ca. 70 million years ago. The origin of crown Coeliadinae skippers is estimated in Indomalaya during the late Eocene ca. 36 million years ago, with subsequent Oligocene colonisation events toward the Australian region and the Afrotropics. Colonisation of the Afrotropics from the Indian region occurred during climatic transition, associated biome shifts, and the closure of the Tethys Ocean, which likely allowed geodispersal through the Arabian Peninsula. The current disjunct distribution of Coeliadinae in the Old World Tropics may result from the emergence of savannahs in the Miocene that progressively replaced woodlands and forests in the Arabian Peninsula and western Asia. Coeliadinae skippers are almost exclusively dicot feeders and were likely extirpated as grasslands became dominant, resulting in the present‐day disjunct distribution of these butterflies.     

Prevention of recurrence and prolonged survival in primary central nervous system lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone

Five patients at risk for primary central nervous system lymphoma (PCNSL) recurrence were treated with high-dose methylprednisolone, (HDMP) to prevent ‘trafficking’ of malignant lymphocytes into the central nervous system (CNS). HDMP was chosen because of its ability to stabilize the ‘blood brain barrier (BBB)’. Three men with newly diagnosed PCNSL, ages 62, 76 and 78 y, whose survival was projected to be 6.6 months, began treatment after achieving complete response (CR) to initial radiation therapy alone and survived 27, 37 and 59 months after treatment. In none was death from recurrent disease in CNS but one patient did die of systemic non-Hodgkin’s lymphoma (NHL) five years after PCNSL diagnosis. A 20 y old man was treated with HDMP after successful combined modality therapy and is alive 75+months after initial diagnosis without evidence of disease recurrence. A 34 y old man relapsed after combined modality initial treatment and failed to respond to HDMP when treatment was begun after unsuccessful salvage therapy; he died of disease 12 months after initial diagnosis. There were no treatment complications. The promising results in this pilot study from the basis for a North Central Cancer Treatment Group (NCCTG) 96-73-51, a Phase 2 clinical trial of brain radiotherapy and HDMP for PCNSL patients 70 y of age and older, a group of patients at high risk for toxicity from intensive combined modality therapy.     

Efficacy of a progressive walking program and glucosamine sulphate supplementation on osteoarthritic symptoms of the hip and knee: a feasibility trial

Introduction  

Management of osteoarthritis (OA) includes the use of non-pharmacological and pharmacological therapies. Although walking is commonly recommended for reducing pain and increasing physical function in people with OA, glucosamine sulphate has also been used to alleviate pain and slow the progression of OA. This study evaluated the effects of a progressive walking program and glucosamine sulphate intake on OA symptoms and physical activity participation in people with mild to moderate hip or knee OA.